Lyell Immunopharma
Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
Business Model:
Revenue: $39.1M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Lyell Immunopharma Information
Geographic Data
Address: 201 Haskins Way
City: South San Francisco
State: CA
Zip: 94080
Country: US
Financial Info
Stage:
Raised Last:
$493M
Raised Total:$493M
Social
Linkedin
Crunchbase
Metrics
4,381,179Website Global Rank
2,283Website Monthly Traffic
Twitter Followers
Description
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Contact Phone:
+16506950677
Contact Email:
Lyell Immunopharma went public on 6/16/2021 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/16/2021
IPO Valuation:
$4B
Ticker Symbol:
LYEL
IPO Price:
$17/share
Amount Raised:
$425M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 3/2020 | Cero Therapeutics | Series A | 0 |
| 2/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 3/2021 | Outpace Bio | Series A | 30M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 3/2020 | Eureka Therapeutics | Series E | 0 |
| 3/2021 | Outpace Bio | Series A | 0 |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2020 | Cero Therapeutics | Series A | 0 |
| 3/2020 | Eureka Therapeutics | Series E | 0 |
| 2/2020 | Sonoma BioTherapeutics | Series A | 0 |
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
